Goldman Sachs Group Inc Lineage Cell Therapeutics, Inc. Transaction History

Goldman Sachs Group Inc

  • $596 Billion
  • Q1 2025

A detailed history of Goldman Sachs Group Inc transactions in Lineage Cell Therapeutics, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 350,103 shares of LCTX stock, worth $231,067. This represents 0.0% of its overall portfolio holdings.

Number of Shares
350,103
Previous 350,103 -0.0%
Holding current value
$231,067
Previous $157,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

21 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 09, 2025
SELL
$0.45 - $0.72 $15,733 - $25,173
-34,963 Reduced 9.08%
350,103 $157,000
Q4 2024

Feb 11, 2025
BUY
$0.5 - $0.95 $70,421 - $133,799
140,842 Added 57.67%
385,066 $192,000
Q3 2024

Nov 14, 2024
BUY
$0.8 - $1.12 $63,712 - $89,196
79,640 Added 48.39%
244,224 $222,000
Q2 2024

Aug 13, 2024
BUY
$0.89 - $1.47 $122,846 - $202,904
138,030 Added 519.81%
164,584 $164,000
Q1 2024

May 15, 2024
SELL
$0.86 - $1.48 $9,367 - $16,121
-10,893 Reduced 29.09%
26,554 $39,000
Q4 2023

Feb 13, 2024
BUY
$0.91 - $1.35 $6,876 - $10,201
7,557 Added 25.28%
37,447 $40,000
Q3 2023

May 14, 2024
SELL
$1.16 - $1.53 $8,766 - $11,562
-7,557 Reduced 20.18%
29,890 $35,000
Q3 2023

Nov 14, 2023
BUY
$1.16 - $1.53 $3,909 - $5,156
3,370 Added 12.71%
29,890 $35,000
Q2 2023

May 14, 2024
SELL
$1.26 - $1.53 $319,093 - $387,470
-253,249 Reduced 90.52%
26,520 $37,000
Q2 2023

Aug 14, 2023
SELL
$1.26 - $1.53 $319,093 - $387,470
-253,249 Reduced 90.52%
26,520 $37,000
Q1 2023

May 14, 2024
BUY
$1.2 - $1.53 $318,828 - $406,505
265,690 Added 1887.14%
279,769 $419,000
Q1 2023

May 11, 2023
BUY
$1.2 - $1.53 $318,828 - $406,505
265,690 Added 1887.14%
279,769 $419,000
Q4 2022

May 14, 2024
SELL
$1.02 - $1.5 $1,421 - $2,091
-1,394 Reduced 9.01%
14,079 $16,000
Q4 2022

Feb 13, 2023
SELL
$1.02 - $1.5 $1,421 - $2,091
-1,394 Reduced 9.01%
14,079 $16,000
Q3 2022

May 14, 2024
SELL
$1.13 - $1.77 $73,106 - $114,511
-64,696 Reduced 80.7%
15,473 $17,000
Q3 2022

Nov 10, 2022
SELL
$1.13 - $1.77 $73,106 - $114,511
-64,696 Reduced 80.7%
15,473 $17,000
Q2 2022

May 14, 2024
BUY
$1.12 - $1.61 $47,848 - $68,782
42,722 Added 114.09%
80,169 $127,000
Q2 2022

Aug 15, 2022
SELL
$1.12 - $1.61 $52,934 - $76,093
-47,263 Reduced 37.09%
80,169 $127,000
Q1 2022

May 16, 2022
BUY
$1.21 - $2.48 $34,815 - $71,357
28,773 Added 29.16%
127,432 $196,000
Q4 2021

Feb 14, 2022
BUY
$1.84 - $2.68 $2,921 - $4,255
1,588 Added 1.64%
98,659 $242,000
Q3 2021

Nov 10, 2021
BUY
$2.26 - $2.86 $219,380 - $277,623
97,071 New
97,071 $245,000

Others Institutions Holding LCTX

# of Institutions
138
Shares Held
108M
Call Options Held
8K
Put Options Held
3K
View Full List

About Lineage Cell Therapeutics, Inc.

LCTX Quotes by TradingView
  • Ticker LCTX
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 169,755,008
  • Market Cap $112M
  • Description
  • Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...
More about LCTX
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email